Regeneron (REGN) Shares Swing as FDA Panel Votes Against Safety of Arcalyst
Tweet
Share
E-mailGet Alerts REGN Hot Sheet
Join SI Premium – FREE
Regeneron Pharma (Nasdaq: REGN) shares have been volatile over the last few minutes as an FDA panel just voted against the safety of the company's Arcalyst for the treatment of gout. Despite a sharp spike lower, Regeneron shares are now mostly unchanged from where the stock was trading prior to the FDA panel headlines.
The stock is down about 11 cents to $130.18.
The stock is down about 11 cents to $130.18.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deutsche sees a buying opportunity in this MedTech stock
- Marvell earnings preview: Is a beat-and-raise quarter possible?
- Citi sees a buying opportunity in this Japanese tech stock
Create E-mail Alert Related Categories
Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
